Berto Acquisition Corp. II (LIXT) investor relations documents from the company's IR site: 3 presentations, 7 press releases; latest deck 2025-10-22. Read in-app with summaries. First-party data.
View Presentation: LIXTE Biotechnology presents LB-100, a first-in-class PP2A inhibitor designed to enhance the efficacy of chemotherapy and immunotherapy in cancer treatment.
| Published | Type | Document |
|---|---|---|
| 2026-07-02 | Press release | LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS |
| 2026-06-26 | Press release | LIXTE Joins Russell Microcap Index |
| 2026-06-18 | Press release | LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026 |
| 2026-06-12 | Press release | LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Ene |
| 2026-06-03 | Press release | LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthen |
| 2026-06-01 | Press release | Download as PDF |
| 2026-04-13 | Press release | Download as PDF |
| 2025-10-22 | Presentation | View Presentation |
| Presentation | View Fact Sheet | |
| Presentation | Investor Fact Sheet - October 2025 |
LIXT overview · LIXT earnings · LIXT financials · LIXT KPIs · LIXT ownership · LIXT peers · LIXT filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.